152 related articles for article (PubMed ID: 37834189)
61. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
[TBL] [Abstract][Full Text] [Related]
62. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
[TBL] [Abstract][Full Text] [Related]
63. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance.
Iqbal MA; Arora S; Prakasam G; Calin GA; Syed MA
Mol Aspects Med; 2019 Dec; 70():3-20. PubMed ID: 30102929
[TBL] [Abstract][Full Text] [Related]
64. miR-205-5p inhibits cell migration and invasion in prostatic carcinoma by targeting ZEB1.
Li L; Li S
Oncol Lett; 2018 Aug; 16(2):1715-1721. PubMed ID: 30008858
[TBL] [Abstract][Full Text] [Related]
65. Exosome-mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR-21.
Jing C; Cao H; Qin X; Yu S; Wu J; Wang Z; Ma R; Feng J
Oncol Lett; 2018 Jun; 15(6):9811-9817. PubMed ID: 29928355
[TBL] [Abstract][Full Text] [Related]
66. Inhibition of DNA methyltransferase 1 by RNA interference reverses epithelial-mesenchymal transition in highly metastatic 95D lung cancer cells by inhibiting the Wnt signaling pathway.
Bu X; Zhang X; Xu J; Yang H; Zhou X; Wang H; Gong L
Oncol Lett; 2018 Jun; 15(6):9242-9250. PubMed ID: 29805653
[TBL] [Abstract][Full Text] [Related]
67. miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K/AKT/Snail signaling of lung cancer cells.
Jia Z; Zhang Y; Xu Q; Guo W; Guo A
Oncol Lett; 2018 May; 15(5):7369-7375. PubMed ID: 29725450
[TBL] [Abstract][Full Text] [Related]
68. CD44 promotes cell proliferation in non-small cell lung cancer.
Hu B; Ma Y; Yang Y; Zhang L; Han H; Chen J
Oncol Lett; 2018 Apr; 15(4):5627-5633. PubMed ID: 29552200
[TBL] [Abstract][Full Text] [Related]
69. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
[No Abstract] [Full Text] [Related]
70. Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.
Tomasello C; Baldessari C; Napolitano M; Orsi G; Grizzi G; Bertolini F; Barbieri F; Cascinu S
Crit Rev Oncol Hematol; 2018 Mar; 123():149-161. PubMed ID: 29482776
[TBL] [Abstract][Full Text] [Related]
71. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
Ricordel C; Friboulet L; Facchinetti F; Soria JC
Ann Oncol; 2018 Jan; 29(suppl_1):i28-i37. PubMed ID: 29462256
[TBL] [Abstract][Full Text] [Related]
72. Downregulation of miR‑205 is associated with glioblastoma cell migration, invasion, and the epithelial-mesenchymal transition, by targeting ZEB1 via the Akt/mTOR signaling pathway.
Chen W; Kong KK; Xu XK; Chen C; Li H; Wang FY; Peng XF; Zhang Z; Li P; Li JL; Li FC
Int J Oncol; 2018 Feb; 52(2):485-495. PubMed ID: 29345288
[TBL] [Abstract][Full Text] [Related]
73. Downregulation of CD24 suppresses bone metastasis of lung cancer.
Okabe H; Aoki K; Yogosawa S; Saito M; Marumo K; Yoshida K
Cancer Sci; 2018 Jan; 109(1):112-120. PubMed ID: 29095550
[TBL] [Abstract][Full Text] [Related]
74. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
75. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Ramalingam SS; Yang JC; Lee CK; Kurata T; Kim DW; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett JC; Thress KS; Jänne PA
J Clin Oncol; 2018 Mar; 36(9):841-849. PubMed ID: 28841389
[TBL] [Abstract][Full Text] [Related]
76. Treating
Mazza V; Cappuzzo F
Appl Clin Genet; 2017; 10():49-56. PubMed ID: 28794650
[TBL] [Abstract][Full Text] [Related]
77. Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer.
Legras A; Pécuchet N; Imbeaud S; Pallier K; Didelot A; Roussel H; Gibault L; Fabre E; Le Pimpec-Barthes F; Laurent-Puig P; Blons H
Cancers (Basel); 2017 Aug; 9(8):. PubMed ID: 28771186
[TBL] [Abstract][Full Text] [Related]
78. Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.
Lee AF; Chen MC; Chen CJ; Yang CJ; Huang MS; Liu YP
PLoS One; 2017; 12(7):e0180383. PubMed ID: 28683123
[TBL] [Abstract][Full Text] [Related]
79. AXL-Driven EMT State as a Targetable Conduit in Cancer.
Antony J; Huang RY
Cancer Res; 2017 Jul; 77(14):3725-3732. PubMed ID: 28667075
[TBL] [Abstract][Full Text] [Related]
80. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
